A Turning Point in the Plague: FDA Approves AZT in 1987

On March 19, 1987, a flicker of hope pierced the despair of the AIDS epidemic. The U.S. Food and Drug Administration (FDA) approved the drug azidothymidine, or AZT, marking the first-ever licensed treatment for HIV/AIDS. For millions facing a terrifying and fatal diagnosis, it was a monumental, if imperfect, breakthrough.

Historical Context

By the mid-1980s, AIDS had become a public health crisis of terrifying proportions. First identified in 1981, the disease was a death sentence, with no treatments to slow its progression. The virus ravaged immune systems, and patients died from opportunistic infections. Public fear was rampant, stigma was severe, and activist groups like ACT UP were demanding action from a government perceived as indifferent.

What Happened

AZT, originally developed as a cancer drug in the 1960s, was found to inhibit HIV replication in the lab. A landmark, albeit short, clinical trial was conducted by Burroughs Wellcome (now part of GlaxoSmithKline). The trial was stopped early in 1986 when a placebo group showed a starkly higher death rate, providing compelling evidence of AZT's efficacy. The FDA, under pressure and utilizing a new accelerated approval process, granted approval in a record 107 days. The drug was marketed under the brand name Retrovir.

Impact & Legacy

AZT's impact was immediate and profound, but complex. It proved that HIV could be targeted pharmacologically, transforming AIDS from an inevitably fatal diagnosis to a manageable chronic condition for those who could access it. However, the drug had severe side effects, was exorbitantly priced, and its long-term efficacy was limited as the virus developed resistance. Its approval galvanized pharmaceutical research, paving the way for the multi-drug "cocktail" therapies introduced in the mid-1990s that truly revolutionized care.

Conclusion

The approval of AZT was a watershed moment. It represented the first concrete victory in the battle against HIV/AIDS, offering life and time. While not a cure, it broke the therapeutic barrier, ignited a research revolution, and gave a desperate community its first weapon, forever changing the trajectory of the epidemic.